Mr. Speaker, I would first like to congratulate my colleague on this excellent bill. I know he has worked very hard, consulted several experts and sought a range of opinions. It really is a remarkable piece of work.
Some people fear that pharmaceutical companies might use the special access programs to circumvent the usual authorization procedures. Does the member have a view on this matter?